Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036343 | 0.92 | PPARG (0.45) | PPARGSCN9AALDH1A1EGLN1TAAR1 | |
| SCHEMBL6035678 | 0.91 | PPARG (0.44) | PPARGSCN9AALDH1A1EGLN1PDE4D | |
| SCHEMBL6035644 | 0.91 | PPARG (0.44) | PPARGSCN9AALDH1A1EGLN1PDE4D | |
| SCHEMBL6034591 | 0.91 | PPARG (0.51) | PPARGSCN9AALDH1A1EGLN1PDE4D | |
| SCHEMBL6035846 | 0.90 | PPARG (0.44) | PPARGSCN9AALDH1A1EGLN1 | |
| SCHEMBL6034788 | 0.89 | PPARG (0.43) | PPARGSCN9AALDH1A1PPARDTAS2R8 | |
| SCHEMBL6034706 | 0.89 | PPARG (0.43) | PPARGSCN9AALDH1A1TAS2R8 | |
| SCHEMBL6035790 | 0.89 | PPARG (0.43) | PPARGSCN9AALDH1A1TAS2R8 | |
| SCHEMBL1633669 | 0.89 | PPARG (0.43) | PPARGSCN9APPARDPPARATAAR1 | |
| SCHEMBL6036165 | 0.88 | PPARG (0.46) | PPARGSCN9AALDH1A1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARG 1037/4885SCN9A 2020/4885ALDH1A1 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.